Proficio Capital Partners LLC Invests $10.77 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

Proficio Capital Partners LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 58,334 shares of the medical research company's stock, valued at approximately $10,768,000. Proficio Capital Partners LLC owned approximately 0.11% of Charles River Laboratories International at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc grew its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Assetmark Inc. grew its position in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. increased its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $59,000. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $56,000. Institutional investors own 98.91% of the company's stock.

Remove Ads

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CRL shares. Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. Robert W. Baird reduced their target price on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. The Goldman Sachs Group reduced their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. dropped their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $191.31.

Charles River Laboratories International Trading Down 1.6 %

Shares of NYSE CRL traded down $2.91 during trading hours on Wednesday, hitting $174.03. The company's stock had a trading volume of 713,559 shares, compared to its average volume of 714,188. The business has a 50-day simple moving average of $167.21 and a 200-day simple moving average of $184.18. The stock has a market cap of $8.90 billion, a price-to-earnings ratio of 1,160.19, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $274.77.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the prior year, the company earned $2.46 earnings per share. The firm's revenue for the quarter was down 1.1% on a year-over-year basis. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).